Check to see if your patient meets any of these criteria18
The International Classification of Diseases (ICD) criteria can also be used to confirm diagnosis of opioid dependence. Click here for more information.
DAILY TREATMENT
PBS Information: This product is listed on the PBS as a Section 100 Opiate Dependence item. Refer to PBS Schedule for full authority information.
Please review full Product Information before prescribing.
BUP-XR, buprenorphine extended release; CDF, cumulative distribution function; COWS, Clinical Opiate Withdrawal Scale; HCP, healthcare professional; IDC, individualised drug counselling; IM, intramuscular; N, population size; OUD, opioid-use disorder; P, p-value; QoL, quality of life; SL, sublingual; SOWS, Subjective Opiate Withdrawal Scale.
1. Australia Bureau of Statistics. Opioid-induced deaths in Australia. 2019. Available at: https://www.abs.gov.au/articles/opioid-induced-deaths-australia. Accessed 11 March 2024. 2. Lalic S, et al. Br J Clin Pharmacol. 2019;85(1):202–215. 3. Lalic S, et al. Br J Clin Pharmacol. 2018;84(6):1267–1278. 4. Australian Institute of Health and Welfare 2018. Opioid harm in Australia and comparisons between Australia and Canada. Cat. no. HSE 210. Canberra: AIHW. 5. Penington Institute (2023). Australia’s Annual Overdose Report 2023. Melbourne: Penington Institute. 6. Larance B, et al. Pain Medicine. 2019;20(4):758–769. 7. Islam MM, et al. Aust NZ J Public Health. 2013;37(2):148–154. 8. Neale J, et al. Health Soc Care Community. 2008;16(2):147–154. 9. NSW Health. NSW clinical guidelines: Treatment of opioid dependence. 2018. 10. Lintzeris N. Medicine Today. 2015;16(6 Suppl):10–15. 11. National Center on Addiction and Substance Abuse at Columbia University (CASA Columbia). Overview of addiction medicine for primary care [PowerPoint presentation]. 2014. Available: https://www.slideshare.net/centeronaddiction/overview-ofaddictionmedicineforprimarycare. Accessed 11 March 2024. 12. Brown RL, et al. Prev Med. 1998;27(1):101–110. 13. Ewing JA. JAMA. 1984;252(14):1905–1907. 14. Skinner HA. Addict Behav. 1982;7(4):363–371. 15. Gavin DR, et al. Br J Addict. 1989;84(3):301–307. 16. Marel C, et al. Appendix W: Drug Abuse Screening Test (DAST-10). 2022. Available at: https://comorbidityguidelines.org.au/appendix-w-drug-abuse-screening-test-dast10/dast10-scoring-and-interpretation. Accessed 16 April 2024. 17. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. Available at: https://www.psychiatry.org/psychiatrists/practice/dsm. Accessed 13 March 2024. 18. American Psychiatric Association. Opioid use disorder. 2018. Available at: https://www.psychiatry.org/patients-families/addiction/opioid-use-disorder. Accessed 13 March 2024. 19. National Institute on Drug Abuse. Drugs, brains, and behavior: the science of addiction. Available at: https://nida.nih.gov/research-topics/addiction-science/drugs-brain-behavior-science-of-addiction. 2020. Accessed 11 March 2024. 20. National Institute on Drug Abuse. Principles of drug addiction treatment: a research-based guide (third edition). 2018. Available at: https://www.drugabuse.gov/publications/principles-drug-addiction-treatment-research-based-guide-third-edition/preface. Accessed 11 March 2024. 21. Gowing L, et al. National guidelines for medication-assisted treatment of opioid dependence. Australian Government National Drug Strategy. 2014. 22. NSW Ministry of Health. Clinical guidelines for use of depot buprenorphine (Buvidal® and Sublocade®) in the treatment of opioid dependence. 2019. Accessed 11 March 2024. 23. SUBOXONE® Film Product Information, March 2021. 24. SUBLOCADE® Product Information, October 2023. 25. Neale J, et al. Harm Reduct J. 2019;16(1):25. 26. Greenwald MK, et al. Biol Psychiatry. 2007;61(1):101–110. 27. Greenwald MK, et al. Drug Alcohol Depend. 2014;144:1–11. 28. Lintzeris N, et al. Addiction. 2002;97(11):1395–1404. 29. Fudala PJ, et al. New Engl J Med. 2003;349(10):949–958. 30. Bickel WK, et al. J Pharmacol Exp Ther. 1988;247(1):47–53. 31. Lintzeris N, et al. National clinical guidelines and procedures for the use of buprenorphine in the maintenance treatment of opioid dependence. 2006. 32. Western Australian Community Pharmacy Program for Opioid Pharmacotherapy (CPOP). Clinical policies and procedures for the use of methadone and buprenorphine in the treatment of opioid dependence. 2014. 33. Haight BR, et al. Lancet. 2019;393(10173):778–790. 34. Nasser AF, et al. J Clin Psychopharmacol. 2016;36(1):18–26. 35. Ling W, et al. J Addict Med. 2019;13(6):442–449. 36. Maremmani I, et al. J Clin Med. 2023;12(17):5575. 37. Lancaster K, et al. Contemp Drug Probl. 2023;50(1):105–120. 38. Wesson DR and Ling W. J Psychoactive Drugs. 2003;35:253–259. 39. Handelsman L, et al. Am J Drug Alcohol Abuse. 1987;13:298–308.
Date of Preparation: May 2024. P-GEN-AU-00224.
You are leaving turntohelp.com.au/hcp,
an Indivior website. Links to all outside websites are provided as a resource to our visitors.
Indivior accepts no responsibility for the content of other sites. Click OK to continue.
